Physician profile
Khalid A Alsherbini
NPI 1720309248
$249,107.32
in general payments reported to CMS, 2019-2025
13 companies · $116K in 2025
The $116K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.89 · 2021: $134 · 2022: $112 · 2023: $33K · 2024: $100K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $242K · Travel and Lodging: $5,301 · Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $241,813.16 |
| Travel and Lodging | $5,300.87 |
| Food and Beverage | $1,700.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $246,196.02 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Ucb, INC. | $2,106.69 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Jazz Pharmaceuticals INC. | $149.85 | 2024 | |
| Medtronic, INC. | $131.57 | 2024 | Activa Pc |
| Sk Life Science, INC. | $126.07 | 2024 | Xcopri |
| Livanova USA, INC. | $120.47 | 2021 | |
| Neurelis, INC. | $88.15 | 2024 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $81.59 | 2024 | |
| Portola Pharmaceuticals, LLC | $26.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.23 | 2025 | Ultomiris |
| Boston Scientific Corporation | $22.93 | 2025 | General - Dbs |
| Medtronic Vascular, INC. | $19.59 | 2019 | |
| Chiesi USA, INC. | $13.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Alsherbini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.